entertainment -WSS

entertainment

author：Wikipedia 2025-09-03 03:37:45 - browse：72

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Is there really a nursing shortage in the U.S.?

WSS

Biden's 'march

Health tech investors get more selective as pandemic boom fades

Study on Amgen’s bispecific immunotherapy produces positive data

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Immune cells and nerve overgrowth may explain recurring UTI pain

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare details structure of new drug price negotiation program

STAT Summit: How researchers deal with rejection

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare: What is it, why does its cyberattack matter?

What does generative AI mean for health care? We asked experts

First over

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Novavax promises a turnaround & Lilly roils the obesity market

Why a market frenzy over new weight loss drugs defies logic

Wikipedia

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Streamlined flu vaccines recommended by FDA advisory panel

Florida health officials providing scant details on measles cases

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Ending the crisis of Black deaths in the U.S.

Why a market frenzy over new weight loss drugs defies logic

Wikipedia

knowledge

entertainment

knowledge